Loading stock data…
Elutia Inc (ELUT)
$0.96-0.04 (-4.25%)
Market ClosedLast close Jun 29
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Elutia Inc. in the Healthcare sector is trading at $0.96 with a market capitalization of $44M. Wall Street consensus targets $5.00 (1 analysts), implying a +422.7% move over the next 12 months. The stock is currently 64% below its 52-week high of $2.64, remaining 0.7% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +422.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.11M↓ | $3.27M↓ | $3.32M↓ | $6.26M↑ | $2.95M |
| Gross Profit | $1.80M↓ | $1.91M↑ | $1.85M↓ | $3.06M↑ | $1.38M |
| Operating Income | -$5.74M↓ | -$5.49M↓ | -$4.36M↑ | -$5.87M↓ | -$4.21M |
| Net Income | -$7.47M↓ | $70.79M↑ | -$3.87M↑ | -$9.61M↓ | -$3.93M |
Peer Comparison
JNJUNHPFE
Fundamentals
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$43.78M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
221.26%
Volume
Today's trading volume
138,300
Recent News
Elutia (ELUT) Q1 2026 Earnings Transcript
Bernadine Cherniak: Thank you, operator, and thank you all for participating in today's call. Earlier today, Elutia released financial results for the first quarter ended March 31, 2026. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Elutia Inc. Q1 2026 Earnings Call Summary
Moby summary of Elutia Inc.'s Q1 2026 earnings call
Elutia Inc (ELUT) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Revenue Shifts
Elutia Inc (ELUT) reports a 6% increase in total net sales and significant progress in its NXT-41 regulatory program, despite challenges in SimpliDerm revenue and increased net loss.
Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Moves Amid ...
Elutia Inc (ELUT) reports a 16% revenue increase and improved gross margins, while navigating operational losses and strategic product shifts.
Elutia Inc. Q4 2025 Earnings Call Summary
Moby summary of Elutia Inc.'s Q4 2025 earnings call